$PVCT India Bound

Peter leaves for India this week for business development activities with prospective regional pharma partners. Ultimately, he will endeavor to determine which entity or entities are appropriate to enter into an MOU regarding PV-10. It would/could be reasonable to expect he'll meet with Ranbaxy Laboratories (majority owned by Daiichi Sankyo), Sun Pharmaceutical Industries (because folks visited the blog from offices in Mumbai's Acme Plaza) and Pfizer India (well, you know my thoughts about Pfizer...), among others.

Sun Pharma is India's largest pharmaceutical company by market capitalization. A Sun Pharma PR last week noted Sun Pharmaceuticals recent market cap was greater than Dr Reddy’s Laboratories, Cipla and Lupin's combined capitalizations.

$PVCT: What Could A Relationship with Daiichi Sankyo Mean?

Daiichi Sankyo's interest in Provectus might range from something simple or narrow to something more robust.

You can read about Daiichi Sankyo's new 5-year business plan here.

$PVCT: Daiichi Sankyo

It appears Daiichi Sankyo is interested in Provectus (based on some very specific information I unearthed that leads me to speculate this). It is not yet clear whether such interest is limited to Japan (and possibly India, through its ownership in Ranbaxy), or whether the Japanese global pharmaceutical company's interest extends to a global license of PV-10.

In February 2011, Daiichi Sankyo announced its acquisition of Plexxikon for $805 million up-front and near-term milestone payments associated with the approval of PLX4032 (vemurafenib, now Zelboraf) for up to an additional $130 million. The deal closed in April.

Other acquisitions include Zepharma (2006), the OTC drugs unit of Astellas Pharma, a majority stake in Indian generic drug maker Ranbaxy (2008) valued at ~$4.6 billion, and U3 Pharma (2008) for the company's anti-HER3 antibody. (See Wikipedia)